Drug therapy for Parkinson's disease

Seminars in Neurology

Volumn 27, Issue 2, 2007, Pages 97-105

  Hermanowicz, Neal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EISENHOWER MEDICAL CENTER   (United States)

Author keywords

COMT inhibition; Dopamine agonists; Dyskinesias; Impulse control disorder; Levodopa; MAO inhibition; Parkinson's disease

Indexed keywords

ACETYLCHOLINE; AMANTADINE; APOMORPHINE; ATROPINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLORGYLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MEMANTINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AGITATION; BODY FLUID; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COMPULSION; CONSTIPATION; DELIRIUM; DIARRHEA; DIZZINESS; DOPAMINERGIC TRANSMISSION; DROWSINESS; DRUG MECHANISM; DRUG WITHDRAWAL; DRY EYE; DYSKINESIA; EATING DISORDER; EVIDENCE BASED MEDICINE; FOOT EDEMA; HALLUCINATION; HOMEOSTASIS; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LEG EDEMA; LIVEDO RETICULARIS; MENTAL DISEASE; MONOTHERAPY; MYDRIASIS; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOMNOLENCE; TREATMENT OUTCOME; URINE COLOR; URINE RETENTION; VISUAL ACUITY; XEROSTOMIA;

ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HUMANS; PARKINSON DISEASE;

EID: 34147176537     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971177     Document Type: Review

References (63)

1. Pahwa R, Factor SA, Lyons KE, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995
2. Miyasaki JM, Shannon K, Voon V, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002
3. Suchowersky O, Gronseth G, Perlmutter J, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-982
4. Onuaguluchi G. Drug treatment of parkinsonism and its assessment. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. New York: John Wiley & Sons Inc; 1968:218-226
5. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;(2):CD003735
6. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-238
7. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-464
8. Cotzias GC, Papavasiliou PS, Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology 1968;18:276-277
9. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379
10. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. Parkinson Study Group. N Engl J Med 2004;351:2498-2508
11. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996;39:37-45
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-1938
13. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491
14. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859
15. Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-78
16. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998;13:885-894
17. Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Juntendo Parkinson Study Group. Mov Disord 2006;21:1384-1395
18. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012-1019
19. Calne DB, Teychenne PF, Claveria LE, et al. Bromocriptine in parkinsonism. BMJ 1974;4:442-444
20. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053
21. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. 043 Study Group. J Neural Transm 2002;109:489-502
22. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539
23. Kurlan R. "Levodopa phobia:" a new iatrogenic cause of disability in Parkinson disease. Neurology 2005;64:923-924
24. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209
25. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728
26. Stocchi F, Hersh BP, Earl NL, Scott BL. Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson's disease. Poster presentation P894, Movement Disorder Society 10th International Congress of Parkinson's Disease and Movement Disorders; Kyoto, Japan: 2006
27. Yoshioka M, Tanaka K, Miyazaki I, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002;43:259-267
28. Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000;107:1165-1173
29. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910
30. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58:1019-1024
31. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006;67:853-858
32. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428
33. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423
34. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006;67:1258-1261
35. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257
36. Hunter KR, Boakes AJ, Laurence DR, Stern GM. Monoamine oxidase inhibitors and L-dopa. Br Med J 1970;3:388
37. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7:295-309
38. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Zydis Selegiline Study Group. Mov Disord 2004;19:426-432
39. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943
40. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248
41. Wu RM, Murphy DL, Chiueh CC. Neuronal protective and rescue effects of deprenyl against MPP + dopaminergic toxicity. J Neural Transm Gen Sect 1995;100:53-61
42. Youdim MB, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001;939:450-458
43. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000;55(suppl 4):S33-S37
44. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089-1095
45. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755
46. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet 1998;352:958
47. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969;208:1168-1170
48. Dallos V, Heathfield K, Stone P, Allen FA. Use of amantadine in Parkinson's disease: results of a double-blind trial. BMJ 1970;4:24-26
49. Scotti G, Spinnler H. Amantadine and Huntington's chorea. N Engl J Med 1971;285:1325-1326
50. Adler CH, Stern MB, Vernon G, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 1997;244:336-337
51. Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998;50:1456-1458
52. Costa A, Peppe A, Dell'Agnello G, et al. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord 2003;15:55-66
53. Molloy SA, Rowan EN, O'Brien JT, et al. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:1323-1328
54. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23
55. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939
56. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518
57. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002;17:1318-1320
58. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-707
59. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001;18:495-505
60. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-518
61. Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol 2006;23:476-481
62. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-745
63. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000;15:305-308